This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Janux Therapeutics’s 8K filing here.
About Janux Therapeutics
Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Read More
- Five stocks we like better than Janux Therapeutics
- Using the MarketBeat Stock Split Calculator
- NVIDIA’s Blackwell Chips Set for Arizona Manufacturing by TSMC?
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Okta: Bullish Signals Suggest a Market Reversal Is Underway
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- BlackRock Makes Waves With $12B Private Credit Acquisition
